Tyler-Stone Wealth Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Tyler-Stone Wealth Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-300	Closed	-$876	–	1006
2024 Q1	$876	Hold	300	–	–	﹤0.01%	905
2023 Q4	$693	Hold	300	–	–	﹤0.01%	886
2023 Q3	$1K	Hold	300	–	–	﹤0.01%	874
2023 Q2	$1K	Buy	+300	New	+$962	﹤0.01%	857
2022 Q4	$4K	Hold	300	–	–	﹤0.01%	694
2022 Q3	$2K	Hold	300	–	–	﹤0.01%	760
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	824
2022 Q1	$3K	Hold	300	–	–	﹤0.01%	726
2021 Q4	$4K	Buy	+300	New	+$6.27K	﹤0.01%	733

Other funds holding ORMP

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tyler-Stone Wealth Management's ORMP Position: Q2 2024 in Review

Tyler-Stone Wealth Management sold out of Oramed Pharmaceuticals (ORMP) in Q2 2024, closing a stake of 300 shares — an estimated $876 sold.

Tyler-Stone Wealth Management first reported a position in ORMP in Q4 2021 and held it in 9 quarters. The position peaked at $4K in Q4 2022. 59 funds tracked by Wall St. Rank hold ORMP as of Q2 2024.

Tyler-Stone Wealth Management reported no remaining Oramed Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Tyler-Stone Wealth Management sold 300 Oramed Pharmaceuticals shares in Q2 2024, an estimated $876.
Tyler-Stone Wealth Management first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Tyler-Stone Wealth Management's Oramed Pharmaceuticals position peaked at $4K in Q4 2022.
59 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2024.

Based on Tyler-Stone Wealth Management's 13F filing for Q2 2024, filed 14 Aug 2024.